Community Schedule

You are currently viewing November 2024

1 results showing for: 'eptacog alfa [recombinant factor viia]'

Eptacog alfa [Recombinant factor VIIa]

[Xpharm]

Inj 1 mg syringe
- Brand Fully subsidised brand. NovoSeven RT
- Pharmacode2404311
- Subsidy $1178.30
- Measure / Qty per 1

Inj 2 mg syringe
- Brand Fully subsidised brand. NovoSeven RT
- Pharmacode2404338
- Subsidy $2356.60
- Measure / Qty per 1

Inj 5 mg syringe
- Brand Fully subsidised brand. NovoSeven RT
- Pharmacode2404346
- Subsidy $5891.50
- Measure / Qty per 1

Inj 8 mg syringe
- Brand Fully subsidised brand. NovoSeven RT
- Pharmacode2427184
- Subsidy $9426.40
- Measure / Qty per 1

For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group. Rare Clinical Circumstances Brand of bypassing agent for >14 days predicted use. Access to funded treatment for >14 days predicted use is by named patient application to the Haemophilia Treaters Group, subject to access criteria.

Rectangle page icon symoblising a PDF. PDF
A tick icon. Fully subsidised
An oval with the number 29 in it. Unapproved medicine under Section 29
An asterisk symbol. 3 or 6 months should be dispensed at once
Two duplicate pages icon. Click to copy
A triangle symbol. Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.
OP Original pack
Sole Subsidised Supply